 Drug Administration Schedule
"Drug Administration Schedule" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
| Descriptor ID |
D004334
|
| MeSH Number(s) |
E02.319.283
|
| Concept/Terms |
Drug Administration Schedule- Drug Administration Schedule
- Administration Schedule, Drug
- Administration Schedules, Drug
- Drug Administration Schedules
- Schedule, Drug Administration
- Schedules, Drug Administration
|
Below are MeSH descriptors whose meaning is more general than "Drug Administration Schedule".
Below are MeSH descriptors whose meaning is more specific than "Drug Administration Schedule".
This graph shows the total number of publications written about "Drug Administration Schedule" by people in this website by year, and whether "Drug Administration Schedule" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1981 | 0 | 3 | 3 | | 1982 | 0 | 1 | 1 | | 1984 | 0 | 1 | 1 | | 1985 | 0 | 3 | 3 | | 1986 | 0 | 2 | 2 | | 1987 | 0 | 2 | 2 | | 1989 | 0 | 1 | 1 | | 1990 | 0 | 3 | 3 | | 1992 | 0 | 2 | 2 | | 1993 | 0 | 1 | 1 | | 1994 | 0 | 5 | 5 | | 1995 | 0 | 2 | 2 | | 1996 | 0 | 3 | 3 | | 1997 | 0 | 6 | 6 | | 1998 | 0 | 8 | 8 | | 1999 | 0 | 5 | 5 | | 2000 | 0 | 5 | 5 | | 2001 | 0 | 9 | 9 | | 2002 | 0 | 12 | 12 | | 2003 | 0 | 9 | 9 | | 2004 | 1 | 4 | 5 | | 2005 | 0 | 9 | 9 | | 2006 | 0 | 14 | 14 | | 2007 | 0 | 12 | 12 | | 2008 | 0 | 9 | 9 | | 2009 | 0 | 14 | 14 | | 2010 | 0 | 9 | 9 | | 2011 | 0 | 6 | 6 | | 2012 | 0 | 5 | 5 | | 2013 | 0 | 9 | 9 | | 2014 | 0 | 9 | 9 | | 2015 | 0 | 11 | 11 | | 2016 | 0 | 10 | 10 | | 2017 | 0 | 4 | 4 | | 2018 | 0 | 6 | 6 | | 2019 | 0 | 5 | 5 | | 2020 | 0 | 10 | 10 | | 2021 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Administration Schedule" by people in Profiles.
-
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Hylander Møller M, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 11 01; 49(11):e1063-e1143.
-
Cheng YC, Guerra Y, Morkos M, Tahsin B, Onyenwenyi C, Fogg L, Fogelfeld L. Insulin management in hospitalized patients with diabetes mellitus on high-dose glucocorticoids: Management of steroid-exacerbated hyperglycemia. PLoS One. 2021; 16(9):e0256682.
-
Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schöffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 10 01; 39(28):3128-3139.
-
Bird LM, Ochoa-Lubinoff C, Tan WH, Heimer G, Melmed RD, Rakhit A, Visootsak J, During MJ, Holcroft C, Burdine RD, Kolevzon A, Thibert RL. The STARS Phase 2 Study: A Randomized Controlled Trial of Gaboxadol in Angelman Syndrome. Neurology. 2021 02 16; 96(7):e1024-e1035.
-
Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thromb Haemost. 2021 Aug; 121(8):1079-1086.
-
Gao JJ, Osgood CL, Gong Y, Zhang H, Bloomquist EW, Jiang X, Qiu J, Yu J, Song P, Rahman NA, Chiu HJ, Ricks TK, Rizvi F, Hou S, Wilson W, Abukhdeir AM, Seidman J, Ghosh S, Philip R, Pierce WF, Bhatnagar V, Kluetz PG, Pazdur R, Beaver JA, Amiri-Kordestani L. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer. Clin Cancer Res. 2021 04 15; 27(8):2126-2129.
-
Sershon RA, Fillingham YA, Abdel MP, Malkani AL, Schwarzkopf R, Padgett DE, Vail TP, Nam D, Nahhas C, Culvern C, Della Valle CJ. The Optimal Dosing Regimen for Tranexamic Acid in Revision Total Hip Arthroplasty: A Multicenter Randomized Clinical Trial. J Bone Joint Surg Am. 2020 Nov 04; 102(21):1883-1890.
-
Yan S, Maro GS, Desai V, Simpson ML. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients. J Manag Care Spec Pharm. 2020 Oct; 26(10):1258-1265.
-
Smits JAJ, Pollack MH, Rosenfield D, Otto MW, Dowd S, Carpenter J, Dutcher CD, Lewis EM, Witcraft SM, Papini S, Curtiss J, Andrews L, Kind S, Conroy K, Hofmann SG. Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2020 06 01; 3(6):e206777.
-
Vaghaiwalla T, Ruhle B, Memeh K, Angelos P, Kaplan E, Liao CY, Polite B, Keutgen X. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery. 2021 01; 169(1):162-167.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|